Drug profile · INN
reboxetine
EDRONAX
reboxetine (EDRONAX) is a norepinephrine transporter inhibitor. Associated with Pfizer Australia Pty Ltd.
Drug details — reboxetine
- Class
- —
- Route
- —
- Patents
- 9
- Programs
- 3
- Data quality
- 0.81
Quick answer
reboxetine (EDRONAX) is a norepinephrine transporter inhibitor. Associated with Pfizer Australia Pty Ltd.
Key facts
Mechanism of action
Norepinephrine transporter inhibitor
Primary target: Sodium-dependent noradrenaline transporter
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12246023
Use of reboxetine to treat narcolepsy
granted -
US 12115165
Use of reboxetine to treat narcolepsy
granted -
US 11957686
Compositions for delivery of reboxetine
granted -
US 11883408
Reboxetine to treat narcolepsy
granted -
US 11364245
Use of reboxetine to treat narcolepsy
granted -
US 11351175
Use of reboxetine to treat narcolepsy
granted -
US 11185547
Use of reboxetine to treat narcolepsy
granted -
US 11135226
Use of reboxetine to treat narcolepsy
granted -
US 11020402
Use of reboxetine to treat narcolepsy
granted
Frequently asked questions
What is reboxetine?
reboxetine (EDRONAX) is a norepinephrine transporter inhibitor. Associated with Pfizer Australia Pty Ltd.
What is the brand name for reboxetine?
EDRONAX is a marketed brand name for reboxetine. Check FDA Drugs@FDA for the current US label holder and prescribing information.